These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 23964615)

  • 41. Cost and Utilization Outcomes After Exclusion of Dipeptidyl Peptidase-4 Inhibitors and Other Diabetes Drug Category Changes in a Self-Funded, State Employee Managed Care Plan.
    King J; McAdam-Marx C; McCaleb R; Davis D; Bemberg GB; Johnson JT
    J Manag Care Spec Pharm; 2019 Jun; 25(6):646-651. PubMed ID: 31134855
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Estimated cost savings associated with the transfer of office-administered specialty pharmaceuticals to a specialty pharmacy provider in a Medical Injectable Drug program.
    Baldini CG; Culley EJ
    J Manag Care Pharm; 2011; 17(1):51-9. PubMed ID: 21204590
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
    Buono JL; Mathur K; Averitt AJ; Andrae DA
    J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect on drug utilization and expenditures of a cost-share change from copayment to coinsurance.
    Klepser DG; Huether JR; Handke LJ; Williams CE
    J Manag Care Pharm; 2007; 13(9):765-77. PubMed ID: 18062728
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.
    Sauer BC; Teng CC; He T; Leng J; Lu CC; Walsh JA; Shah N; Harrison DJ; Tang DH; Cannon GW
    J Med Econ; 2016; 19(1):34-43. PubMed ID: 26337538
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Shifting Cost-drivers of Health Care Expenditures in Inflammatory Bowel Disease.
    Click B; Lopez R; Arrigain S; Schold J; Regueiro M; Rizk M
    Inflamm Bowel Dis; 2020 Jul; 26(8):1268-1275. PubMed ID: 31671186
    [TBL] [Abstract][Full Text] [Related]  

  • 47. What Contributes Most to High Health Care Costs? Health Care Spending in High Resource Patients.
    Pritchard D; Petrilla A; Hallinan S; Taylor DH; Schabert VF; Dubois RW
    J Manag Care Spec Pharm; 2016 Feb; 22(2):102-9. PubMed ID: 27015249
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Claims for disease-modifying therapy by Alberta non-insured health benefits clients.
    Barnabe C; Healy B; Portolesi A; Kaplan GG; Hemmelgarn B; Weaselhead C
    BMC Health Serv Res; 2016 Aug; 16(1):430. PubMed ID: 27557840
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Utilization and costs of medical services and prescription medications for rheumatoid arthritis among recipients covered by a state Medicaid program: a retrospective, cross-sectional, descriptive, database analysis.
    Khanna R; Smith MJ
    Clin Ther; 2007 Nov; 29(11):2456-67. PubMed ID: 18158087
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Specialty drug spending trends among Medicare and Medicare Advantage enrollees, 2007-11.
    Trish E; Joyce G; Goldman DP
    Health Aff (Millwood); 2014 Nov; 33(11):2018-24. PubMed ID: 25367998
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Direct costs of opioid abuse in an insured population in the United States.
    White AG; Birnbaum HG; Mareva MN; Daher M; Vallow S; Schein J; Katz N
    J Manag Care Pharm; 2005; 11(6):469-79. PubMed ID: 15998164
    [TBL] [Abstract][Full Text] [Related]  

  • 52. One-Year Outcomes of an Integrated Multiple Sclerosis Disease Management Program.
    Groeneweg M; Forrester SH; Arnold B; Palazzo L; Zhu W; Yoon P; Scearce T
    J Manag Care Spec Pharm; 2018 May; 24(5):458-463. PubMed ID: 29694287
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost and utilization of behavioral health medications associated with rescission of an exemption for prior authorization for severe and persistent mental illness in the Vermont Medicaid Program.
    Simeone JC; Marcoux RM; Quilliam BJ
    J Manag Care Pharm; 2010 Jun; 16(5):317-28. PubMed ID: 20518584
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drug utilization and cost in a Medicaid population: a simulation study of community vs. mail order pharmacy.
    Valluri S; Seoane-Vazquez E; Rodriguez-Monguio R; Szeinbach SL
    BMC Health Serv Res; 2007 Jul; 7():122. PubMed ID: 17663768
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of Carving in Pharmacy Benefits on Utilization and Costs.
    Parekh N; Papa S; Drnach A; Spiegel L; Huang Y; Manolis C; Good CB
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1317-1324. PubMed ID: 32996397
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Utilization and cost of sildenafil in a large managed care organization with a quantity limit on sildenafil.
    Cooke CE; Wong W; Lee H
    J Manag Care Pharm; 2005 Oct; 11(8):674-80. PubMed ID: 16194131
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
    Khandker RK; Kruzikas DT; McLaughlin TP
    J Manag Care Pharm; 2008 Jun; 14(5):426-41. PubMed ID: 18597572
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Analysis of pharmacist-provided medication therapy management (MTM) services in community pharmacies over 7 years.
    Barnett MJ; Frank J; Wehring H; Newland B; VonMuenster S; Kumbera P; Halterman T; Perry PJ
    J Manag Care Pharm; 2009; 15(1):18-31. PubMed ID: 19125547
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of pharmacy benefit design on prescription drug utilization: a fixed effects analysis of plan sponsor data.
    Roebuck MC; Liberman JN
    Health Serv Res; 2009 Jun; 44(3):988-1009. PubMed ID: 19187183
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluating the Effect of Treatment Persistence on the Economic Burden of Moderate to Severe Psoriasis and/or Psoriatic Arthritis Patients in the U.S. Department of Defense Population.
    Lee S; Xie L; Wang Y; Vaidya N; Baser O
    J Manag Care Spec Pharm; 2018 Jul; 24(7):654-663. PubMed ID: 29952710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.